BindingDB logo
myBDB logout

151 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27132867 154 Structure-guided development of dual▀2 adrenergic/dopamine D2 receptor agonists.EBI Friedrich-Alexander University
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26704965 229 Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.EBI University of Illinois at Chicago
26709102 142 Discovery of Vibegron: A Potent and Selective▀3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.EBI Merck Research Laboratories
26471092 23 Molecular hybridization yields triazole bronchodilators for the treatment of COPD.EBI Pfizer
26125514 40 Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human▀3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.EBI Asahi Kasei Pharma Corporation
25695425 62 Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors.EBI City University of New York
25629394 52 Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist..EBI Theravance Biopharma, Inc.
25065493 92 The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting▀2-adrenoceptor agonist.EBI Novartis Institutes for BioMedical Research
24881566 140 Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI GlaxoSmithKline
25241924 47 The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.EBI Novartis Institutes for BioMedical Research
24835980 98 Discovery of TD-4306, a long-acting▀2-agonist for the treatment of asthma and COPD.EBI Theravance, Inc.
24878222 50 Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors.EBI Pfizer Inc.
24813741 110 Multivalent design of long-acting▀(2)-adrenoceptor agonists incorporating biarylamines.EBI Theravance, Inc.
16640337 47 Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.EBI GlaxoSmithKline
23614528 121 Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists.EBI University of Nottingham
21870877 119 Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors.EBI University of Nottingham
11806709 63 Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.EBI GlaxoSmithKline
22932315 28 An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol.EBI Novartis Institutes for BioMedical Research
22079756 219 From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists.EBI AstraZeneca
22178551 46 A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD.EBI Theravance, Inc.
21925889 48 The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group.EBI GlaxoSmithKline Medicines Research Centre
21696967 51 The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings.EBI GlaxoSmithKline Medicines Research Centre
21723724 91 Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists.EBI AstraZeneca
21652207 17 Design driven HtL: The discovery and synthesis of new high efficacyß2-agonists.EBI AstraZeneca
20462258 50 Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.EBI GlaxoSmithKline Medicines Research Centre
19317397 62 Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.EBI GlaxoSmithKline Medicines Research Centre
19146417 70 The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.EBI GlaxoSmithKline Pharmaceuticals
18433113 124 Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.EBI GlaxoSmithKline
9548813 53 The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.EBI SmithKline Beecham Pharmaceuticals
21486038 177 Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.EBI H. Lundbeck A/S
22563707 27 A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design.EBI Radboud University Nijmegen Medical Centre
22313227 78 Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.EBI National Institute of Mental Health
21207959 69 Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.EBI National Institute of Mental Health
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
20684563 176 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.EBI H. Lundbeck A/S
20181479 177 Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.EBI Merck Research Laboratories
19963380 38 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.EBI Hunter College and the Graduate Center of the City University of New York
19821575 47 Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.EBI GlaxoSmithKline
19608416 29 Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.EBI Astellas Pharma Inc
19168263 14 Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.EBI Instituto Polit£cnico Nacional
19581100 162 Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc.
19232786 72 Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc.
18651730 123 Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.EBI Astellas Pharma Inc
18307290 97 Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.EBI Astellas Pharma Inc.
17897826 18 The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.EBI Pfizer Global Research and Development
17498952 4 The discovery of long acting beta2-adrenoreceptor agonists.EBI Pfizer Global Research and Development
16451077 86 Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.EBI Pfizer Inc.
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
15603933 28 Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.EBI Fujisawa Pharmaceutical Co. Ltd
15324892 9 Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity.EBI Novartis Horsham Research Centre
12213075 70 Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).EBI Purdue University
11311069 64 (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists.EBI Wyeth-Ayerst Research
8691440 22 Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.EBI University of Pennsylvania
7658429 31 (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).EBI Abbott Laboratories
15203136 37 (+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.EBI Virginia Commonwealth University
22182578 13 Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the humanß2-adrenoceptor.EBI Instituto Polit£cnico Nacional
21863888 9 Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease.EBI Pfizer Inc.
21783363 10 Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44.EBI University of Toronto
21591752 41 Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.EBI Soochow University College of Pharmaceutical Sciences
20036561 39 Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.EBI Medical University of Lublin
21615150 14 Progress in structure based drug design for G protein-coupled receptors.EBI Heptares Therapeutics Limited
21075627 26 Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.EBI Pfizer Inc.
21353541 25 Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.EBI Merck Research Laboratories
21310610 63 Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.EBI Theravance, Inc.
20833036 221 Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization.EBI 4SC AG
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20804199 23 Inhalation by design: novel ultra-long-actingß(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.EBI Pfizer Inc.
20655218 72 A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.EBI Novartis Institutes for BioMedical Research
20620058 41 Smoothened antagonists for hair inhibition.EBI Pfizer Inc.
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20434333 111 A vHTS approach for the identification of beta-adrenoceptor ligands.EBI 4SC AG
20402514 34 The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.EBI Novartis Institutes for Biomedical Research
20384344 42 Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.EBI Meiji Seika Kaisha, Ltd.
20096576 41 Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
19857969 6 Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines.EBI National Institute of Diabetes and Digestive and Kidney Diseases
19646882 72 Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.EBI University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and the Informatics Institute of UMDNJ
19646865 45 Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.EBI Pfizer Global Research and Development
19643607 26 Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
19875286 44 Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.EBI Boehringer Ingelheim Pharma GmbH& Co KG
19492813 56 Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.EBI GlaxoSmithKline
19366244 138 Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.EBI Astellas Pharma Inc.
19362005 74 Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc
19081260 10 Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.EBI Central Drug Research Institute
18829308 5 Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.EBI Lundbeck Research USA, Inc.
18656910 2 Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol.EBI Centre for Addiction and Mental Health
18573659 47 Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.EBI GlaxoSmithKline
18553954 126 Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.EBI Astellas Pharma Inc.
18507369 85 Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.EBI Theravance, Inc.
18180157 10 Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains.EBI St. Jude Children's Research Hospital
17911024 37 Potent oxindole based human beta3 adrenergic receptor agonists.EBI Lilly Research Laboratories
17804228 44 Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.EBI Lilly Research Laboratories
17632003 55 Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.EBI Pfizer Global Research and Development
17571866 49 Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.EBI National Institute of Mental Health
17533126 78 Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17524641 69 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.EBI GlaxoSmithKline
17506540 52 Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.EBI Medical University of Lublin
17303428 22 Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes.EBI Università degli Studi di Milano
16931005 21 Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.EBI Lilly Research Laboratories
16392798 46 Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.EBI Columbia University College of Physicians and Surgeons
15686912 35 Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety.EBI Dainippon Pharmaceutical Co., Ltd
15546708 35 Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.EBI Dainippon Pharmaceutical Co., Ltd
15546707 60 Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.EBI Dainippon Pharmaceutical Co., Ltd
14643338 118 Binding of beta-carbolines at 5-HT(2) serotonin receptors.EBI Virginia Commonwealth University
12798332 35 Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists.EBI Wyeth Research
12657269 52 Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines.EBI Dainippon Pharmaceutical Co., Ltd.
12361399 17 Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding.EBI Universita di Camerino
12270184 34 Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines.EBI Wyeth Research
12270183 45 Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines.EBI Wyeth Research
11327605 27 New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.EBI Wyeth-Ayerst Research
11277513 25 2,4-Thiazolidinediones as potent and selective human beta3 agonists.EBI Wyeth-Ayerst Research
11212115 72 Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.EBI Merck Research Laboratories
11055339 59 Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.EBI Merck Research Laboratories
11052788 33 Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.EBI Merck Research Laboratories
10999482 52 Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.EBI Merck Research Laboratories
10987429 69 Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.EBI Merck Research Laboratories
10915043 69 Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.EBI Merck Research Laboratories
10888325 90 Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.EBI Merck Research Laboratories
10888324 48 Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.EBI Merck Research Laboratories
10406657 91 Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.EBI Merck Research Laboratories
10360736 2 S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp.EBI Kirin Brewery Co., Ltd.
10340609 15 L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.EBI Merck Research Laboratories
10201842 69 Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.EBI Merck Research Laboratories
10201841 47 Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.EBI Merck Research Laboratories
9873681 65 3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.EBI Merck Research Laboratories
9873496 80 3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.EBI Merck Research Laboratories
9871717 72 Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.EBI Merck Research Laboratories
9871716 93 Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.EBI Merck Research Laboratories
9379432 36 Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prEBI Abbott Laboratories
1648138 33 Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands.EBI Universitá di Catania
21926995 79 Ligand discovery from a dopamine D3 receptor homology model and crystal structure.BDB University of California San Francisco
8699 51 Beta adrenergic receptor binding in membrane preparations from mammalian brain.BDB TBA
19245211 9 Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.BDB Intervet Innovation GmbH
15655528 75 The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.BDB University of Nottingham
18783211 14 Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands.BDB Monash University